Exosome cancer diagnostic reaches market

Abstract

General Hospital, now the scientific founder and CSO of Exosome Diagnostics, was first author on a study that found exosomes could contribute to tumor growth through the transport of mRNA, miRNA and angiogenic proteins—and that these could also provide blood-based diagnostic information (Nat. Cell Biol. 10, 1470– 1476, 2008). Their role as a vehicle for cell-to-cell communication is now generally accepted. “The most important thing to understand is exosomes go everywhere—they can enter almost any tissue,” Kalluri says. Exosomes are fairly inert, but they fuse with the cell membrane, deliver a payload and change the biology of the recipient cell—hence their potential as nanoscale drug delivery vehicles or gene therapy vectors. “These things behave a little like an enveloped virus,” says Codiak’s Williams, formerly executive vice president of R&D at Biogen. They even have potential as cancer vaccines, as exosomes derived from antigen-presenting cells contain intact major histocompatibility complexes and are capable of antigen presentation (J. Immunol. 193, 1006– 1011, 2014). Another key thread in the exosome diagnostics story is in pancreatic cancer. In a recent 250-patient study, Kalluri and colleagues found glypican-1 (GPC1), a cell surface proteoglycan, specifically enriched in circulating exosomes from individuals with pancreatic cancer. GPC1 Exosome cancer diagnostic reaches market

DOI: 10.1038/nbt0416-359
02004002014201520162017
Citations per Year

229 Citations

Semantic Scholar estimates that this publication has 229 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Sheridan2016ExosomeCD, title={Exosome cancer diagnostic reaches market}, author={Cormac Sheridan}, journal={Nature Biotechnology}, year={2016}, volume={34}, pages={359-360} }